Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic Disorders

 Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic Disorders

Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic Disorders

Shots:
  • Axovant acquires WW development and commercialization rights for AXO-AAV-GM1 and AXO-AAV-GM2
    Program and will make payments to University of Massachusetts
  • The focus of the agreement is to develop functional copies of HEXA, HEXB & GLB1 genes encoding the certain enzymes to treat Gm1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases
  • AXO-AAV-GM1 program is initiated for GLB1 gene using AAV vector for activating β-gal enzyme
    activity to treat GM1 gangliosidosis, with its expected results in H2’19
  • AXO-AAV-GM2 is programmed for HEXA and HEXB genes developed via AAVrh8 vectors to activate Hex
    A enzyme activity for both Tay-Sachs and Sandhoff diseases, with its expected results in H1’19

Click here to read full press release/ article | Ref: Axovant Sciences | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post